Publikationen, an denen er mitarbeitet MARÍA LINARES GÓMEZ (22)

2024

  1. Correction to: Detection of kinase domain mutations in BCR::ABL1 leukemia by ultra-deep sequencing of genomic DNA (Scientific Reports, (2022), 12, 1, (13057), 10.1038/s41598-022-17271-3)

    Scientific Reports

  2. Digital Microscopy Augmented by Artificial Intelligence to Interpret Bone Marrow Samples for Hematological Diseases

    Microscopy and Microanalysis, Vol. 30, Núm. 1, pp. 151-159

  3. Impact of viral hepatitis therapy in multiple myeloma and other monoclonal gammopathies linked to hepatitis B or C viruses

    Haematologica, Vol. 109, Núm. 1, pp. 272-282

  4. Short-Chain Fatty Acid Production by Gut Microbiota Predicts Treatment Response in Multiple Myeloma

    Clinical Cancer Research

2023

  1. Posttranslational splicing modifications as a key mechanism in cytarabine resistance in acute myeloid leukemia

    Leukemia, Vol. 37, Núm. 8, pp. 1649-1659

2022

  1. Detection of kinase domain mutations in BCR::ABL1 leukemia by ultra-deep sequencing of genomic DNA

    Scientific Reports, Vol. 12, Núm. 1

  2. High-Throughput CRISPR Screening in Hematological Neoplasms

    Cancers, Vol. 14, Núm. 15

2021

  1. Monitoring of clonal evolution of acute myeloid leukemia identifies the leukemia subtype, clinical outcome and potential new drug targets for post-remission strategies or relapse

    Haematologica, Vol. 106, Núm. 9, pp. 2325-2333

  2. Myc‐related mitochondrial activity as a novel target for multiple myeloma

    Cancers, Vol. 13, Núm. 7

  3. Pathogenetic and prognostic implications of increased mitochondrial content in multiple myeloma

    Cancers, Vol. 13, Núm. 13

2020

  1. Improving the prediction of acute myeloid leukaemia outcomes by complementing mutational profiling with ex vivo chemosensitivity

    British Journal of Haematology, Vol. 189, Núm. 4, pp. 672-683

  2. Protein carbonylation and lipid peroxidation in hematological malignancies

    Antioxidants, Vol. 9, Núm. 12, pp. 1-30

2019

  1. A novel deep targeted sequencing method for minimal residual disease monitoring in acute myeloid leukemia

    Haematologica, Vol. 104, Núm. 2, pp. 288-296

  2. A precision medicine test predicts clinical response after idarubicin and cytarabine induction therapy in AML patients

    Leukemia Research, Vol. 76, pp. 1-10

  3. Collaborative intelligence and gamification for on-line malaria species differentiation

    Malaria Journal, Vol. 18, Núm. 1

  4. Concurrent progressive multifocal leukoencephalopathy and central nervous system infiltration by multiple myeloma: A case report

    Journal of Oncology Pharmacy Practice, Vol. 25, Núm. 4, pp. 998-1002

  5. Dual PAK4-NAMPT inhibition impacts growth and survival, and increases sensitivity to DNA-damaging agents in Waldenstrom € macroglobulinemia

    Clinical Cancer Research, Vol. 25, Núm. 1, pp. 369-377

  6. MEK inhibition enhances the response to tyrosine kinase inhibitors in acute myeloid leukemia

    Scientific reports, Vol. 9, Núm. 1, pp. 18630

  7. Protein carbonylation in patients with myelodysplastic syndrome: An opportunity for deferasirox therapy

    Antioxidants, Vol. 8, Núm. 11

  8. Ruxolitinib in combination with prednisone and nilotinib exhibit synergistic effects in human cells lines and primary cells from myeloproliferative neoplasms

    Haematologica, Vol. 104, Núm. 5, pp. 937-946